Physician profile
Dmitry Tchapyjnikov
NPI 1740547496
$918.78
in general payments reported to CMS, 2019-2025
13 companies · $98.17 in 2025
The $98.17 reported for 2025 was less than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $244 · 2020: $71.47 · 2021: $175 · 2022: $39.87 · 2023: $144 · 2024: $147 · 2025: $98.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $388.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $218.27 | 2021-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Ucb, INC. | $205.14 | 2019-2025 | Fintepla |
| Eisai INC. | $145.00 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $81.28 | 2022-2024 | Epidiolex |
| Zogenix INC. | $73.20 | 2021 | |
| Neurelis, INC. | $34.89 | 2024 | Valtoco |
| Immedica Pharma US, INC. | $34.11 | 2024 | |
| Acadia Pharmaceuticals INC | $28.05 | 2024 | Daybue |
| Ptc Therapeutics, INC. | $27.34 | 2024 | |
| Genentech USA, INC. | $18.60 | 2023 | Evrysdi |
| Greenwich Biosciences, INC. | $18.00 | 2021 | |
| Itf Therapeutics LLC | $17.45 | 2025 | |
| Novo Nordisk INC | $17.45 | 2023 | Sogroya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dmitry Tchapyjnikov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.